Morgan M - Search Results

1

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group. Schlenk RF, et al. Among authors: morgan m. N Engl J Med. 2008 May 1;358(18):1909-18. doi: 10.1056/NEJMoa074306. N Engl J Med. 2008. PMID: 18450602 Free article.

2

Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling.

Morgan MA, Dolp O, Reuter CW. Morgan MA, et al. Blood. 2001 Mar 15;97(6):1823-34. doi: 10.1182/blood.v97.6.1823. Blood. 2001. PMID: 11238126 Free article.

3

Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.

Morgan MA, Ganser A, Reuter CW. Morgan MA, et al. Leukemia. 2003 Aug;17(8):1482-98. doi: 10.1038/sj.leu.2403024. Leukemia. 2003. PMID: 12886235 Review.

4

Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors.

Morgan MA, Wegner J, Aydilek E, Ganser A, Reuter CW. Morgan MA, et al. Leukemia. 2003 Aug;17(8):1508-20. doi: 10.1038/sj.leu.2403022. Leukemia. 2003. PMID: 12886237

5

Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.

Morgan MA, Sebil T, Aydilek E, Peest D, Ganser A, Reuter CW. Morgan MA, et al. Br J Haematol. 2005 Sep;130(6):912-25. doi: 10.1111/j.1365-2141.2005.05696.x. Br J Haematol. 2005. PMID: 16156861 Free article.

6

Going from genes to proteins in myelodysplastic syndromes.

Ganser A, Morgan MA, Weissinger EM. Ganser A, et al. Among authors: morgan ma. Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1109-10. doi: 10.1073/pnas.0610831104. Epub 2007 Jan 19. Proc Natl Acad Sci U S A. 2007. PMID: 17237221 Free PMC article. No abstract available.

7

Targeting the RAS signaling pathway in malignant hematologic diseases.

Morgan MA, Ganser A, Reuter CW. Morgan MA, et al. Curr Drug Targets. 2007 Feb;8(2):217-35. doi: 10.2174/138945007779940043. Curr Drug Targets. 2007. PMID: 17305500 Review.

8

Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma.

Reuter CW, Morgan MA, Grünwald V, Herrmann TR, Burchardt M, Ganser A. Reuter CW, et al. Among authors: morgan ma. World J Urol. 2007 Mar;25(1):59-72. doi: 10.1007/s00345-007-0152-0. Epub 2007 Mar 6. World J Urol. 2007. PMID: 17340158 Review.

9

Proteome analysis in hematology using capillary electrophoresis coupled on-line to mass spectrometry.

Weissinger EM, Mischak H, Kontsendorn J, Hahn A, Hahn N, Morgan M, Ganser A. Weissinger EM, et al. Among authors: morgan m. Mini Rev Med Chem. 2009 May;9(5):627-3. doi: 10.2174/138955709788167583. Mini Rev Med Chem. 2009. PMID: 19456293 Review.

10

Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.

Damm F, Heuser M, Morgan M, Yun H, Grosshennig A, Göhring G, Schlegelberger B, Döhner K, Ottmann O, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Döhner H, Heil G, Ganser A, Krauter J. Damm F, et al. Among authors: morgan m. J Clin Oncol. 2010 Feb 1;28(4):578-85. doi: 10.1200/JCO.2009.23.0342. Epub 2009 Dec 28. J Clin Oncol. 2010. PMID: 20038731

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

5,052 results

Search Page